No association between glutathione-synthesis-related genes and Japanese schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 1, 2011, Pages 39-46

  Hanzawa, Ryo ^a   Ohnuma, Tohru ^a   Nagai, Yasuhito ^a   Shibata, Nobuto ^a   Maeshima, Hitoshi ^a   Baba, Hajime ^a   Hatano, Tokiko ^a   Takebayashi, Yuto ^a   Hotta, Yuri ^a   Kitazawa, Maiko ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

glutamate cysteine ligase; glutathione; glutathione synthetase; polymorphism; schizophrenia

Indexed keywords

GLUTAMATE CYSTEINE LIGASE; GLUTAMATE CYSTEINE LIGASE CATALYTIC SUBUNIT; GLUTAMATE CYSTEINE LIGASE MODIFIER; GLUTATHIONE; GLUTATHIONE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CATATONIC SCHIZOPHRENIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEBEPHRENIA; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE SYNTHASE; HAPLOTYPES; HUMANS; JAPAN; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 79251545774     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2010.02157.x     Document Type: Article

References (23)

1. Davis KL, Kahn RS, Ko G, Davidson M,. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991; 148: 1474-1486.
2. Olney JW, Farber NB,. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995; 52: 998-1007.
3. Marchbanks RM, Ryan M, Day IN, Owen M, McGuffin P, Whatley SA,. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr. Res. 2003; 65: 33-38.
4. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004; 9: 684-697. (Pubitemid 38932173)
5. Yao JK, Reddy RD, van Kammen DP,. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287-310.
6. Rabinovic AD, Hastings TG,. Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 1998; 71: 2071-2078.
7. Smythies JR,. Oxidative reactions and schizophrenia: a review-discussion. Schizophr. Res. 1997; 24: 357-364.
8. Choi YB, Lipton SA,. Redox modulation of the NMDA receptor. Cell. Mol. Life Sci. 2000; 57: 1535-1541.
9. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH,. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994; 12: 1031-1040.
10. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A,. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009; 33: 1178-1183.
11. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000; 12: 3721-3728.
12. Yao JK, Leonard S, Reddy R,. Altered glutathione redox state in schizophrenia. Dis. Markers 2006; 22: 83-93.
13. Waziri R, Baruah S, Sherman AD,. Abnormal serine-glycine metabolism in the brains of schizophrenics. Schizophr. Res. 1993; 8: 233-243.
14. Maeshima H, Ohnuma T, Sakai Y, et al. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia-Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 1410-1418.
15. Ohnuma T, Sakai Y, Maeshima H, et al. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008; 32: 1905-1912.
16. Meister A, Anderson ME,. Glutathione. Annu. Rev. Biochem. 1983; 52: 711-760.
17. Huang CS, Anderson ME, Meister A,. Amino acid sequence and function of the light subunit of rat kidney gamma-glutamylcysteine synthetase. J. Biol. Chem. 1993; 268: 20578-20583.
18. Huang CS, Chang LS, Anderson ME, Meister A,. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J. Biol. Chem. 1993; 268: 19675-19680.
19. Tosic M, Ott J, Barral S, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 2006; 79: 586-592.
20. Ma J, Li DM, Zhang R, et al. Genetic analysis of glutamate cysteine ligase modifier (GCLM) gene and schizophrenia in Han Chinese. Schizophr. Res. 2010; 119: 273-274.
21. Kishi T, Ikeda M, Kitajima T, et al. Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. Ann. N. Y. Acad. Sci. 2008; 1139: 63-69.
22. Matsuzawa D, Hashimoto K, Hashimoto T, et al. Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150B: 86-94.
23. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 16621-16626.